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Abstract: Spontaneous joint bleeding and repeated hemarthroses lead to hemophilic arthropathy—a
debilitating disease with a significant negative impact on mobility and quality of life. Iron, cytokines,
and angiogenic growth factors play a pivotal role in the onset of the inflammatory process that
involves the synovial tissue, articular cartilage, and subchondral bone, with early damages and
molecular changes determining the perpetuation of a chronic inflammatory condition. Synovitis
is one of the earliest complications of hemarthrosis, and is characterized by synovial hypertrophy,
migration of inflammatory cells, and a high degree of neo-angiogenesis with subsequent bleeding.
The pathogenic mechanisms and molecular pathways by which blood in the joint cavity causes
articular cartilage and subchondral bone destruction have yet to be fully elucidated. Both cytokines
and matrix metalloproteinases and hydroxyl radicals may induce chondrocyte apoptosis. Members
of the tumor necrosis factor receptor superfamily (such as the molecular triad: osteoprotegerin—OPG;
receptor activator of nuclear factor κB—RANK; RANK ligand—RANKL) seem instead to play a
major role in the inflammatory process. These pathogenic processes interact with each other and
ultimately lead to a fibrotic joint and the disabling condition characteristic of hemophilic arthropathy.
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1. Introduction
Hemophilia A and B are X-linked congenital bleeding disorders caused by the absence or decrease
of clotting factor VIII (FVIII) or factor IX (FIX), respectively. In patients with severe hemophilia (i.e.,
plasma FVIII or FIX < 1 U/dL), joint bleeding is the most frequent manifestation in both children
and in adults [1,2]. The benefits of the prophylactic administration of clotting factor concentrates
(CFCs) to prevent the arthropathy have been defined. CFCs can be used as primary prophylaxis
in the absence of documented osteochondral joint disease, before the second clinically evident joint
bleeding, and with age of 3 years. Instead, they can be used as secondary prophylaxis after two or
more bleedings into target joints and before the onset of clinically documented joint disease, as well
as tertiary prophylaxis in the presence of overt joint disease. It is noteworthy that the use of CFCs
can reduce the risk of hemarthrosis, even if the risk of bleedings is not completely prevented [3].
Recurrent joint bleedings induce joint damage in about eighty percent of the patients, with knees,
elbows, and ankles as preferential target joints.
Hemophilic arthropathy is a disabling condition characterized by joint impairment, chronic pain,
and reduced quality of life [4,5]. Recent evidence indicates that intra-articular inflammation and
angiogenesis may be pivotal processes in the pathogenic cascade of hemophilic arthropathy [6]. Joint
bleeding favors iron release from hemoglobin, thus inducing a chronic inflammatory process mediated
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by cytokines and pro-angiogenic factors and consequently leading to progressive synovial pannus
growth and articular cartilage damage [7–11]. Interestingly, a close relationship between the type of
gene mutation and the clinical phenotype of hemophilia has been demonstrated. In fact, it appears
that “null” mutations and/or missense mutations may significantly affect the severity of hemophilic
arthropathy either in patients with hemophilia A or in those with hemophilia B [12].
2. Pathophysiology of Hemophilic Arthropathy
The pathophysiology of hemophilic arthropathy shares some clinical and biological features with
rheumatoid arthritis (RA) and osteoarthritis (OA), especially RA-related synovitis and bone resorption
and OA-related articular cartilage degeneration.
2.1. From Synovitis to Articular Cartilage Damage
In hemophilic arthropathy, both inflammatory and degenerative mechanisms contribute
to articular cartilage degeneration, although these processes may even occur independently.
Intra-articular blood effusion-derived hemosiderin deposits are thought to be critical in the early
phase of hemophilic arthropathy through the induction of a proliferative disorder with chronic
synovitis which then extends to the articular cartilage surface, ultimately resulting in destructive
arthropathy [13–16]. However, according to other authors, the initial pathogenic process might
rather involve articular cartilage damage due to the iron-catalyzed formation of destructive oxygen
metabolites resulting in chondrocyte apoptosis, with synovial inflammatory changes being secondary
or parallel to the process of cartilage damage [13].
Recent studies point toward the implication of a high molecular weight complex in the hemophilic
arthropathy-related inflammatory process. Indeed, the so-called “inflammasome” has been highlighted
as a crucial factor which regulates the maturation and secretion of pro-inflammatory interleukin (IL)-1β.
Iron also seems to play a crucial role in the induction of the expression of several pro-inflammatory
cytokines, including IL-1α, IL-6, and tumor necrosis factor (TNF)-α (Figure 1) [17]. Moreover,
it appears that iron is involved in the initiation of synovial pannus growth by dysregulating
the expression of critical genes such as c-myc and mdm2, which are responsible for synoviocyte
proliferation [18–21]. Synovitis is an inflammatory process involving synovial tissue, characterized
by hypertrophy, migration of inflammatory cells, and a high degree of neo-angiogenesis. In addition,
IL-1α, IL-6, IL-1β, and TNF-α activate monocytes/macrophages, triggering a catabolic program with
the production of nitric oxide (NO), proteases such as matrix metalloproteinases (MMPs), tissue
plasminogen activator, and other matrix components [19,22,23]. These in turn can act on T cells,
fibroblasts, and osteoclasts through a variety of inflammatory mediators, leading to articular cartilage
and subchondral bone destruction.
As demonstrated by Jansen et al. [24], monocytes/macrophages are mostly responsible for the
irreversible inhibition of cartilage matrix synthesis and the induction of chondrocyte apoptosis. In
particular, elevated levels of IL-1β produced by activated monocytes/macrophages further increase
the release of hydrogen peroxide by chondrocytes with the formation of cytotoxic hydroxyl radicals
sited very close to the chondrocytes (Figure 1) [17,19]. Moreover, there are also direct harmful effects
exerted by intra-articular blood on cartilage, as demonstrated by in vitro studies. Indeed, it has been
reported that a short four-day exposure of human cartilage to whole blood at concentrations up to
50% may induce long-lasting inhibition of cartilage matrix proteoglycan synthesis and a prolonged
decrease in proteoglycan content [25–29].
In this complex scenario, the role of neo-angiogenesis also deserves careful consideration.
In fact, neo-angiogenesis—a process implicated in tumor growth and inflammatory arthritis—is
also a critical independent mechanism involved in hemophilic arthropathy [15]. Pro-angiogenic
vascular endothelial growth factor (VEGF) is a pivotal signaling molecule involved in angiogenesis,
can be induced by hypoxia and some cytokines, and acts mainly through the interaction with its
receptors, VEGFR-1 and VEGFR-2 [6,13,16]. Studies on the formation of synovial pannus in other
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joint diseases reported an increased oxygen demand with evidence of de novo blood vessel formation
in the synovium [11,30]. In patients with severe hemophilia, either elevated circulating levels of
VEGF-A or increased synovial expression of VEGF-A have been reported, which suggests an important
role of this powerful pro-angiogenic mediator in the pathogenesis of hemophilic arthropathy-related
synovitis [6,31]. Interestingly, a direct correlation between high serum VEGF-A levels and disease
activity has also been demonstrated in RA [7,10]. In particular, increased microvessel density and the
expression of VEGF have been shown in the synovium of severe hemophilic arthropathy patients with
advanced joint disease [32]. These data indicate that the advanced stage of hemophilic arthropathy is
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arthropathy with some similarities  to RA,  few studies have clearly demonstrated  their  functional 
role  in the pathogenic cascade of the disease  [18].  In  fact, hemophilic arthropathy has been  firstly 
described as a degenerative rather than an inflammatory joint disease [34]. However, recent studies 
indicate  that  hemophilic  arthropathy  has  similarities  either with  the  degenerative  joint  damage 
occuring  in OA  or with  the  chronic  inflammatory  process  associated with  RA,  even  if  specific 
pathogenetic mechanisms have not yet been fully elucidated [35]. 
A  crucial  regulator  of  bone  biology  is  the molecular  triad  osteoprotegerin  (OPG)/receptor 
activator  of  nuclear  factor  κB  (RANK)/RANK  ligand  (RANKL)  [36,37], which  controls  the  local 
changes  in  bone  turnover  and  represents  a  key pathway  triggering  bone  resorption  induced  by 
inflammation. RANKL is a transmembrane ligand mainly expressed on osteoblasts/stromal cells in 
the bone microenvironment. It is synthesized by lymphocytes and synovial cells, and may induce 
osteoclastogenesis  through  a mechanism  enhanced  by  several  cytokines  (e.g.,  TNF‐α,  IL‐1,  and 
IL‐17) that promote both inflammation and bone resorption [38,39]. By binding to its receptor RANK 
which  is  expressed  on  the  cell  surface  of  osteoclast  precursors,  RANKL  induces  osteoclast 
Figure 1. Schematic representation of the e f blood-induced joint damage in hemophilia.
The role f iron (Fe2+) interacting with hydrogen peroxide (H2O2), activation of macr phages (Mo/Mφ),
matrix metalloproteinases (MMPs), and pro-inflammatory cytokines is highl ghted. Adapted with
permission from [17]. IL: i terleukin; RBC: red blood cell.
2.2. Bone Damage
The mechanisms by which the bleeding in hemophilic arthropathy leads to subchondral bone
damage and loss are not yet clear. In hemophilic arthropathy patients, osteoporosis characterized by
bone loss was often related to the presence of infectious comorbidities and their treatment. However,
it was shown that osteoporosis in patients with hemophilic arthropathy may even be independent of
the aforementioned factors [33].
Even though some cytokines have been related to the pathogenesis of synovitis in hemophilic
arthropathy with some similarities to RA, few studies have clearly demonstrated their functional role
in th pathogenic cascade of the disease [18]. In fact, hemophilic arthropathy has be n firstly described
as a degenerative rather than an inflammatory jo nt disease [34]. However, r cent studies in icate that
hemoph lic arthropathy has similarities either wi h the degenerative joint damage occuring in OA or
with t e chronic inflammatory process associated with RA, even if specific pathogenetic mechanisms
have not yet been fully elucidated [35].
A crucial regulator of bone biology is the molecular triad osteoprotegerin (OPG)/receptor
activator of nuclear factor κB (RANK)/RANK ligand (RANKL) [36,37], which controls the local
changes in bone turnover and represents a key pathway triggering bone resorption induced by
inflammation. RANKL is a transmembrane ligand mainly expressed on osteoblasts/stromal cells in
the bone microenvironment. It is synthesized by lymphocytes and synovial cells, and may induce
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osteoclastogenesis through a mechanism enhanced by several cytokines (e.g., TNF-α, IL-1, and IL-17)
that promote both inflammation and bone resorption [38,39]. By binding to its receptor RANK which
is expressed on the cell surface of osteoclast precursors, RANKL induces osteoclast differentiation and
maturation, thus fostering bone resorption. In this scenario, OPG acts as a decoy receptor for RANKL,
and competes for the binding of RANKL to RANK [40–42]. By this mechanism, OPG negatively
regulates osteoclast differentiation, activity, and survival both in vivo and in vitro, thus effectively
inhibiting bone resorption [37,39,42]. Accordingly, any change in the balance between OPG and
RANKL may lead to pathological bone remodeling. A high prevalence of osteoporosis has been
reported among hemophiliacs, which is related to the severity of arthropathy and is enhanced by
HIV infection. Therefore, increased bone resorption does not seem to be balanced by a comparable
bone formation in these patients [43,44]. Of note, the triad OPG/RANK/RANKL may act as key
regulator of bone remodeling in synovial tissue of adult hemophiliacs, as suggested by decreased
OPG levels and the strong expression of RANK and RANKL (Figure 2) [45,46]. Moreover, a strict
correlation between the severity of hemophilic arthropathy and instrumental findings, such as the
World Federation of Hemophilia (WFH) orthopaedic joint scale [47], Petterson [48], and ultrasound
(US) [49] scores, has been reported [45]. The molecular markers of bone turnover in the synovial tissue
of hemophiliacs clearly indicate an osteoclastic activation which is not counteracted by OPG [45].
In fact, RANK and RANKL were found to be strongly expressed in the synovium, independently of the
type of treatment. Instead, the expression of OPG was dramatically reduced in the synovial tissue of
hemophilic arthropathy patients [45]. The almost complete absence of OPG expression in hemophilic
arthropathy synovial tissue represents an important issue, because it implies that the bone turnover
balance is shifted toward osteoclastic activity, and thus bone resorption. Furthermore, there is in vitro
evidence that the reduction of thrombin production results in less thrombin-induced PAR-1 mediated
proliferation of osteoblasts [3]. Collectively, these findings indicate that bone damage in hemophilic
arthropathy is a complex multifactorial process.
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Figure  2.  Photomicrographs  showing  the  expression  of  receptor  activator  of  nuclear  factor‐κB 
(RANK), RANK ligand (RANKL), and osteoprotegerin (OPG) in synovial tissue from patients with 
hemophilia A, hemophilia B, and osteoarthritis. Representative photomicrographs of tissue sections 
subjected  to  immunoperoxidase  staining  for RANK, RANKL, and OPG  (brownish‐red  color) and 
counterstained with hematoxylin are shown. Arrows indicate OPG immunostaining in the synovial 
lining layer. Original magnification: ×20. Scale bar: 100 μm. Reproduced with permission from [46]. 
Figure 2. Photomicrographs showing the expression of receptor activator of nuclear factor-κB (RANK),
RANK ligand (RANKL), and osteoprotegerin (OPG) in synovial tissue from patients with hemophilia
A, hemophilia B, and oste arthritis. Representative photomicrographs of tissue secti ns subjected to
immunoperoxid se sta ning for RANK, RANKL, and OPG (brownish-red color) and counterstained
with hematoxylin are shown. Arrows indicate OPG immunostaining in the synovial lining layer.
Original magnification: ×20. Scale bar: 100 µm. Reproduced with permission from [46].
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3. Evidence That Arthropathy May be More Severe in Hemophilia A than in Hemophilia B
Recent investigations suggest that patients with severe hemophilia B may have a less-severe
disease compared to patients with severe hemophilia A [12,50,51]. In a recent study, a large cohort
of patients with hemophilia A and B was evaluated by employing clinical, imaging, and biochemical
markers [46]. A significantly worse WFH score and US score were observed in hemophilia A patients
compared with hemophilia B patients [46]. Indeed, the US score showed lower mean values for the
hemophilia B patient group compared to the hemophilia A patient group. Furthermore, the evidence
of lower values of WFH score in the hemophilia B patient group has strengthened the sonographic
result. Interestingly, most of the US findings (e.g., effusion, synovial hypertrophy with flags on power
Doppler, hemosiderin deposition, bone remodeling, cartilage modifications) were mainly observed
in the hemophilia A patient group. Moreover, the correlation between the number of hemarthroses
and the severity of the disease has been investigated. The results showed a greater percentage of
hemarthroses in the hemophilia A patient group than in the hemophilia B patient group, even when
matched for age. In addition, possible differences in the RANK/RANKL/OPG molecular triad
between hemophilia A and B patients were analyzed [46]. A lower expression of OPG was found in the
synovial tissue of patients with hemophilia A compared with hemophilia B, which further highlight
the greater severity of arthropathy in the hemophilia A patient group (Figure 2). This evidence was
further confirmed by the analysis of serum OPG levels, which resulted significantly lower in patients
with hemophilia A than in patients with hemophilia B [46].
4. Conclusions
In summary, although the complex molecular mechanisms underlying the abnormal synovial
overgrowth in hemophilic arthropathy are still poorly understood, recent studies have demonstrated
that a variety of mediators may play an important role in blood-induced joint damage. Collectively,
such mediators are believed to trigger a synovial over-reaction which, once started, may act
independently of the intra-articular bleeding. Indeed, hemarthrosis leads to intra-articular iron
deposition, synovial proliferation and neo-angiogenesis, and cartilage and subchondral bone damage,
triggering a vicious cycle resulting in severe arthropathy. Although bone damage may arise from
a multifactorial process in patients with hemophilia, hemarthrosis seems to be a major contributor.
This complex scenario ultimately leads to the clinical manifestation of hemophilic arthropathy, which
has a more severe phenotype in hemophilia A than in hemophilia B patients.
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